Stolt-Nielsen Limited
LONDON, February 11, 2021 – Stolt-Nielsen Limited (Oslo Børs: SNI) announced today that the Company's Board of Directors recommended a final dividend for 2020 of $0.25 per Common Share, payable on May 5, 2021 to shareholders of record as of April 22, 2021. In accordance with the normal settlement practice, the shares will trade ex-dividend on and after April 21, 2021.
The dividend, which is subject to shareholder approval, will be voted on at the Company's Annual General Meeting of Shareholders scheduled for April 15, 2021 in Bermuda.
For additional information please contact:
Jens F. Grüner-Hegge
Chief Financial Officer
U.K. +44 (0) 20 7611 8985
j.gruner-hegge@stolt.com
Ellie Davison
Head of Corporate Communications
U.K. +44 (0) 20 7611 8926
e.davison@stolt.com
About Stolt-Nielsen Limited
Stolt-Nielsen (SNL or the ‘Company’) is a long-term investor and manager of businesses focused on opportunities in logistics, distribution and aquaculture. The Stolt-Nielsen portfolio consists of its three global bulk-liquid and chemicals logistics businesses – Stolt Tankers, Stolthaven Terminals and Stolt Tank Containers – Stolt Sea Farm and a number of LNG investments. Stolt-Nielsen Limited is listed on the Oslo Stock Exchange (Oslo Børs: SNI).
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Eavor Technologies Inc.17.10.2025 18:00:00 CEST | Press release
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom